The "Peptide Therapeutics Market: Industry Trends and Global Forecasts, Till 2040 - Distribution by Type of Peptide, Route of Administration, Key Therapeutic Area and Geographical Regions" has been added to ResearchAndMarkets.com's offering.

The peptide therapeutics market is poised for significant growth, projected to escalate from USD 84.2 billion in 2023 to USD 162.4 billion by 2035, marking a CAGR of 6.8%. These therapeutics, built from polypeptides, are increasingly crucial in treating a spectrum of conditions, including metabolic diseases, cancer, and hormone-related ailments. Over 100 peptide-based therapies have received FDA approval across various countries, underscoring their importance and efficacy.

Peptide therapeutics such as Tirzepatide (Mounjaro), and Lupkynis stand as leading examples in combating chronic ailments like diabetes and cancer. The surge in chronic conditions amplifies demand for biologics including peptides, known for their high specificity, safety, low toxicity, and minimized off-target effects. Pharmaceutical companies are advancing drug conjugates, particularly peptide drug conjugates, to expand the therapeutic frontier addressing diverse diseases. Recent advancements have seen peptide drugs gain approval for type 2 diabetes, obesity, and cancers, setting a promising trajectory for future market growth.

Market Insights:

• The peptide therapeutics arena includes 25 approved drugs and over 280 in development, signifying a robust pipeline tackling various diseases.
• An ongoing evaluation of peptides for diversified delivery methods focuses primarily on metabolic and oncological disorders.
• Intensifying competition drives innovation, encouraging differentiation in clinical and commercial strategies.
• Global clinical trials of peptides number over 1,200, with metabolic disease treatments prevailing in research focus.
• Collaborative activities have amplified, emphasizing licensing of technology and products.
• Investments exceeding USD 7 billion from public and private sectors, across more than 200 instances, highlight expected favorable returns.
• Prominent pharmaceutical entities are engaging in proprietary product development and strategic investments, aiming to harness market potential.

Market Segmentation and Regional Insights

Medium-sized peptides dominate the market, benefiting from their balanced properties. With a market share nearing 65% today, the segment continues to flourish. Small peptides, applicable in targeted therapies, anticipate a growth CAGR exceeding 20% through the forecast period. Subcutaneous administration prevails due to enhanced efficacy, comprising 65% of the market. Driven by non-invasive administration demand, topical methods are expected to grow at a 30% CAGR.

Metabolic disease management represents over 60% of the market, propelled by the urgency for treatments addressing diabetes and obesity. The respective market for gastrointestinal issues is projected to expand by a remarkable 25% CAGR. Regionally, North America leads market share, driven by an increase in chronic conditions. This trend is evident as the US reports around 129 million individuals with chronic diseases, reinforcing demand for peptides. The Asia-Pacific region anticipates a relatively higher growth rate during the forecast period.

Key Industry Players: Apellis Pharmaceuticals, BioLineRx, Eli Lilly, FirstString Research, Novo Nordisk, Palatin Technologies, RegeneRx Biopharmaceuticals, Stealth BioTherapeutics, Takeda, Zealand Pharma.

Report Coverage:

• Comprehensive market sizing and opportunity analysis across peptide types, administration routes, therapeutic areas, and regions.
• A detailed landscape assessment of 300 peptide therapies either launched or under development based on development phases, peptide types, and therapeutic focus.
• Profiles on leading companies highlight foundational details and future projections.
• Analysis on big pharma initiatives, focus on administration routes, and partnerships fosters deep market understanding.
• Review of funding dynamics, clinical trials, and novel peptide drug case studies.

Why Purchase This Report?

• Detailed revenue projections and analysis provide value for established players and new entrants.
• Comprehensive insights into competitive and market dynamics inform strategic decisions.
• An understanding of market drivers, barriers, opportunities, and challenges aids in the strategic alignment for growth.

Key Attributes

A selection of companies mentioned in this report includes, but is not limited to:

• 13therapeutics
• 7 Med Health Ventures
• 9 Meters Biopharma
• Abbott
• Abingworth
• Acorn Bioventures
• ACT Capital Management
• Adage Capital Management
• Adams Street Partners
• Advanced Accelerator Applications
• Aileron Therapeutics
• AJU IB Investment
• Akashi Therapeutics
• Alexion Pharmaceuticals
• Allysta Pharmaceuticals
• Alphabet venture arm
• Altimmune
• Amgen
• Amolyt Pharma
• Ampio Pharmaceuticals
• Amyndas Pharmaceuticals
• Andera Partners
• Angiochem
• Anji Pharmaceuticals
• AOP Orphan Pharmaceuticals
• Apellis Pharmaceuticals
• Apeptico
• APIM Therapeutics
• Apitope
• Aquestive Therapeutics
• Arch Biopartners
• ARCH Venture Partners
• Arix Bioscience
• Asahi Kasei
• AsclepiX Therapeutics
• Astellas Pharma
• AstraZeneca

For more information about this report visit https://www.researchandmarkets.com/r/8cp6dl

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260114661833/en/